Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | USP8 | P40818 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29935957 | 1.00 | PIK3CD (0.51) | PIK3CDHPGDSPLA2G2AMAPTKMT2A | |
| SCHEMBL362305 | 0.79 | SRC (0.39) | HPGDSMAPTKMT2AALDH1A1USP8 | |
| SCHEMBL10325263 | 0.79 | HPGDS (0.39) | PIK3CDHPGDSMAPTKMT2AALDH1A1 | |
| SCHEMBL1846308 | 0.79 | HPGDS (0.39) | PIK3CDHPGDSMAPTKMT2AALDH1A1 | |
| SCHEMBL18036083 | 0.78 | CYP11B1 (0.44) | PIK3CDHPGDSMAPTALDH1A1USP8 | |
| SCHEMBL1006358 | 0.78 | MAPT (0.46) | PIK3CDHPGDSMAPTKMT2AALDH1A1 | |
| SCHEMBL30976940 | 0.77 | PIK3CD (0.47) | PIK3CDKMT2AALDH1A1MEN1ADORA1 | |
| SCHEMBL23482226 | 0.75 | USP8 (0.37) | PIK3CDHPGDSMAPTKMT2AALDH1A1 | |
| SCHEMBL23458907 | 0.75 | HPGDS (0.36) | PIK3CDHPGDSMAPTALDH1A1USP8 | |
| SCHEMBL29919284 | 0.75 | HPGDS (0.36) | PIK3CDHPGDSMAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327435-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. | 2024-10-03 | — | — | US | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024140679-A1 | SPIROCYCLIC HPK1 ANTAGONISTS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-07-04 | — | — | WO | disclosed |
| EP-4323356-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | Nuvalent, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221227-A9 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2022221227-A9 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20220363696-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | EGFR, ERBB2, ERBB3 | PIK3CD 269/4885HPGDS 1073/4885PLA2G2A 4133/4885 |
| US-20220363696-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | EGFR, ERBB2, ERBB4 | PIK3CD 160/4885HPGDS 1048/4885PLA2G2A 4156/4885 |
| US-20240327435-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | EGFR, ERBB2, ERBB4 | PIK3CD 160/4885HPGDS 1048/4885PLA2G2A 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.